알림

Vertex Pharmaceuticals (VRTX)

NasdaqGS: VRTX · 실시간 가격 · USD

551.34

+23.15 (4.38%)

종가 기준: Aug 18, 2026, 3:59 PM

4.38% (1D)

매수호가	544.38
시가총액	138.91B
매출 (ttm)	12.59B
순이익 (ttm)	4.41B
베타	0.30
EPS (ttm)	17.17
P/E (ttm)	31.92
선행 P/E	25.12
P/B (ttm)	6.86
P/S (ttm)	11.03
Earnings Date	Nov 2, 2026

매도호가	545
거래량	860,619
평균 거래량 (20일)	1,567,301
시가	534.72
전일 종가	528.19
일중 범위	532.88 - 551.88
52주 범위	374.17 - 551.98
애널리스트	Buy
목표주가	570 (3.38%)
배당	n/a
배당락일	n/a

VRTX 소개

Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of...

[더 보기]

산업 Biotechnology

섹터 Healthcare

IPO 일자 Jul 24, 1991

직원 수 6,400

상장 거래소 NasdaqGS

티커 VRTX

웹사이트 https://www.vrtx.com

전체 기업 정보

재무 실적

2025년 Vertex Pharmaceuticals의 매출은 12B로, 전년 11.02B 대비 8.9% 증가했습니다. 순이익은 3.95B로, -838.09% 감소했습니다.

재무제표

애널리스트 전망

애널리스트 25명의 투자의견을 종합하면 VRTX 주식의 평균 등급은 "Buy"입니다. 12개월 목표주가는 570로, 최근 주가 대비 3.38% 상승 여력입니다.

주가 전망

어닝 서프라이즈

Vertex Pharmaceuticals가 Aug 3, 2026에 분기 실적을 발표했습니다:

매출 $3.33B 예상치 하회 $0, 및 12.45% 전년 대비 성장.

EPS 4.73 예상치 하회 -0.02, 및 4.65% 전년 대비 성장.

다음 실적 발표

Vertex Pharmaceuticals의 실적 발표 예정일은 Nov 2, 2026, 정규장 중입니다.
애널리스트 예상 매출은 ... 업그레이드

뉴스

1일 전 · StockStory

3 Cash-Producing Stocks on Our Watchlist

Businesses with strong free cash flow tend to be more adaptable and resilient. Some of these companies shine bright by using their cash wisely to strengthen their market positions.

4일 전 · Insider Monkey

Can AbCellera Biologics (ABCL)’s Vertex Pharmaceuticals Incorporated (VRTX) Deal Turn its TCE Platform Into a Breakthrough?

On July 29, AbCellera Biologics Inc. (NASDAQ:ABCL) and Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) announced a strategic collaboration to research, develop, and commercialize multispecific T-cel...

4일 전 · Simply Wall St.

Is Vertex Pharmaceuticals (VRTX) Fairly Valued As Pipeline Catalysts Near?

Vertex Pharmaceuticals stock has delivered a strong 5 year return, yet current checks suggest the market now prices it roughly in line with its fundamentals rather than as an obvious bargain. Recent n...

4일 전 · Motley Fool

Vertex Pharmaceuticals Just Hit an All-Time High. Here's Why the Biotech Stock Could Soar Even More

The drugmaker should significantly mitigate its most important risk as it develops new products.

4일 전 · Simply Wall St.

Vertex Pharmaceuticals (VRTX) Could Be 8% Undervalued Following Raised 2026 Guidance

Vertex Pharmaceuticals (VRTX) has drawn fresh attention after reporting second quarter 2026 results, raising full year revenue guidance to US$13.1b to US$13.2b, and completing a US$1.42b share repurch...

2 페이지 중 1

Vertex Pharmaceuticals (VRTX)